Funding to support a cancer diagnostic system to measure empirical treatment response Houston, TX, July 20, 2023 - EMPIRI, Inc., who is revolutionizing how we treat cancer by providing empirical, personalized, drug response data prior to treatment selection, today announced the award of a Phase I NSF SBIR grant in support of EMPIRI’s automation of their E-Slice platform. This grant will support further development of a first in class cancer diagnostic system that can deliver

San Francisco, CA, Jan 8, 2023– EMPIRI today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view EMPIRI’s presentation live, and also access a recorded version beginning November 29th – SIX weeks prior to the actual event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week. Dr. Kyuson Yun, cofounder, will be presenting EMPIR

At the 11th annual Texas Life Science Forum, held on November 8, 2022, EMPIRI Inc. was once again recognized as one of the Rice Alliance Most Promising Life Science Companies for our E-Slice technology. Hosted by BioHouston and Rice Alliance for Technology and Entrepreneurship, the Texas Life Sciences Forum presents panels and networking opportunities to grow the life sciences field. It also hosted over 50 companies to pitch their solutions for improvement. Chosen by inve

Humbled and thrilled to receive our NIH/NCI R01 grant! It is a 5-year $3.07M grant for a prospective clinical trial with our E-Slice assay to predict Triple Negative Breast Cancer patient treatment responses to standard of care. Huge thanks to collaborators Dr. Kyuson Yun, Houston Methodist/Weill-Cornell Med, and Dr. Naoto Ueno at MD Anderson Cancer Center. #E-Slice #NIH #NCI # R01 #TNBC #MDACC #HMRI #Breastcancer #Immunotherapy #Cancertreatment #Precisiononcology